NCT02567955View on ClinicalTrials.gov

Immunogenicity and Safety of Gardasil-9 and Cervarix

PHASE3CompletedINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2017

Conditions
HPV Vaccines Immunogenicity and Safety
Interventions
BIOLOGICAL

Immunogenicity two doses of Gardasil-9

Subjects will receive two standard doses of Gardasil-9 (0.5 ml)

BIOLOGICAL

Immunogenicity Cervarix and Gardasil-9

Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)

Trial Locations (1)

G1E7G9

Équipe de recherche en vaccination, Québec

All Listed Sponsors
lead

Laval University

OTHER

NCT02567955 - Immunogenicity and Safety of Gardasil-9 and Cervarix | Biotech Hunter | Biotech Hunter